SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c (SWITCH)
Randomized, Cross Over, Controlled, Multi-centric Study to Assess Whether Type 1 Diabetic Patients in Sub-optimal Glycemic Control Can Improve Using the Continuous Glucose Values of the MiniMed Paradigm REAL-Time Insulin Pump System Versus the MiniMed Paradigm Insulin Pump
Sponsor: Medtronic Diabetes
A NA clinical study on Diabetes Mellitus, Type 1, this trial is completed. The trial is conducted by Medtronic Diabetes and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed NA
-
Oct 2019 — Jan 2021 [monthly]
Completed NA
Phase: PHASE4 → NA
-
Jun 2018 — Oct 2019 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medtronic Diabetes
For direct contact, visit the study record on ClinicalTrials.gov .